Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer
Vishwajith Sridharan(Massachusetts General Hospital), Jonathan D. Schoenfeld(Brigham and Women's Hospital), Guilherme Rabinowits(Baptist Hospital of Miami), Jun Zhou(Brigham and Women's Hospital), Mariano Severgnini(Dana-Farber Cancer Institute), Roy B. Tishler(Dana-Farber Cancer Institute), Danielle N. Margalit(Harvard University), Robert I. Haddad(Georgetown University), Stephanie Lynch(Brigham and Women's Hospital), F. Stephen Hodi(Harvard University), Peter S. Hammerman(Broad Institute), Nicole G. Chau(University of British Columbia), Jochen H. Lorch(Northwestern University)
Cited by 85
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k